Disease · MONDO_0001056
Comparisons in its trials124
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 124
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| S-1/Cisplatin vs 5-FU/Cisplatin: serious adverse events | 257 of 521 | 248 of 508 | 1,029 | NCT00400179 | Trial comparisons |
| Mitomycin Plus Short-term Fluoropyrimidine vs Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati: serious adverse events | 3 of 422 | 5 of 425 | 847 | NCT00296335 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 299 of 385 | 318 of 388 | 773 | NCT01774786 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | 178 of 385 | 156 of 388 | 773 | NCT01774786 | Trial comparisons |
| Bevacizumab vs Placebo: serious adverse events | 134 of 386 | 137 of 381 | 767 | NCT00548548 | Trial comparisons |
| TAS-118/Oxaliplatin vs S-1/Cisplatin: deaths from any cause | 22 of 352 | 8 of 348 | 700 | NCT02322593 | Trial comparisons |
| TAS-118/Oxaliplatin vs S-1/Cisplatin: serious adverse events | 155 of 352 | 159 of 348 | 700 | NCT02322593 | Trial comparisons |
| Everolimus 10mg / Daily vs Placebo: serious adverse events | 210 of 437 | 89 of 215 | 652 | NCT00879333 | Trial comparisons |
| Fluoropyrimidine/Cisplatin (FP) vs Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H): serious adverse events | 81 of 290 | 106 of 294 | 584 | NCT01041404 | Trial comparisons |
| mFOLFOX6 + Zolbetuximab vs mFOLFOX6+ Placebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 278 of 279 | 277 of 278 | 557 | NCT03504397 | Trial comparisons |
| Surgery + Adjuvant Chemotherapy (SC) vs Neoadjuvant Chemotherapy +Surgery +Adjuvant Chemotherapy (CSC): deaths from any cause | 91 of 264 | 78 of 266 | 530 | NCT01515748 | Trial comparisons |
| Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2: Overall Survival | 82 of 263 | 62 of 262 | 525 | NCT01924533 | Trial comparisons |
| Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2: Number of Patients With Objective Response. | 44 of 263 | 28 of 262 | 525 | NCT01924533 | Trial comparisons |
| Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2: Progression-Free Survival (PFS) | 47 of 263 | 29 of 262 | 525 | NCT01924533 | Trial comparisons |
| Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2: deaths from any cause | 181 of 263 | 200 of 262 | 525 | NCT01924533 | Trial comparisons |
| Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2: serious adverse events | 92 of 262 | 65 of 259 | 521 | NCT01924533 | Trial comparisons |
| TAS-102+BSC vs Placebo+BSC: deaths from any cause | 252 of 335 | 141 of 168 | 503 | NCT02500043 | Trial comparisons |
| TAS-102+BSC vs Placebo+BSC: serious adverse events | 143 of 335 | 70 of 168 | 503 | NCT02500043 | Trial comparisons |
Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2: Number of Patients With Deterioration of Health Related Quality of Life (HRQoL) as Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 Item Module (QLQ-C30) Global HRQoL Scale | 160 of 240 | 177 of 249 | 489 | NCT01924533 | Trial comparisons |
| Rivoceranib Plus Best Supportive Care (BSC) vs Placebo Plus BSC: deaths from any cause | 283 of 307 | 134 of 151 | 458 | NCT03042611 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001056/comparisons